Kenney Christopher John's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Mar 13, 2026
- Accession no.
- 0001193125-26-106727
- Filed
- Mar 13, 2026
- Trade date
- Mar 12-13, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $77.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kenney Christopher JohnCIK 0001880129 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Common Shares | MOption exerciseAcquired | +3,750 | –F1 | – | 8,479 | Direct | |
| Mar 13, 2026 | Common Shares | SSaleDisposed | −1,410 | $55.23 | −$77,874.3 | 7,069 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Common Shares | MOption exerciseDisposed | −3,750 | $0.00 | $0 | 11,250 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.
Referenced by the price of 1 transaction in Table I.